Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange.

A series of single-chain anti-CD20 antibodies was produced by fusing single-chain Fv (scFv) with human IgG1 hinge and Fc regions, designated scFv-Fc. The initial scFv-Fc construct was assembled using an 18 amino acid (aa) linker between the antibody light- and heavy-chain variable regions, with the Cys residue in the upper hinge region (Kabat 233) mutagenized to Ser. Anti-CD20 scFv-Fc retained specific binding to CD20-positive cells and was active in mediating complement-dependent cytolysis. Size-exclusion HPLC analysis revealed that the purified scFv-Fc included multimeric as well as monomeric components. Variant scFv-Fcs were constructed incorporating four different hinges between the scFv and Fc regions, or three different linkers in the scFv domain. All formed multimers, with the highest level of multimerization found in the scFv-Fc with the shortest linker (8 aa). Elimination of an unusual salt bridge between residues L38 and H89 in the V(L)-V(H) domain interface failed to reduce the formation of higher order forms. Structural analysis of the scFv-Fc constructed with 18 or 8 aa linkers by pepsin or papain cleavage suggested the proteins contained a form in which scFv units had cross-paired to form a 'diabody'. Thus, domain exchange or cross-pairing appears to be the basis of the observed multimerization.

[1]  J. Novotný,et al.  Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  U. Hellman,et al.  Improvement of an "In-Gel" digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. , 1995, Analytical biochemistry.

[4]  J. Ledbetter,et al.  Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. , 1999, Journal of immunology.

[5]  L. Gordon,et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Lawson,et al.  Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. , 1994, Protein engineering.

[7]  S. Ho,et al.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. , 1989, Gene.

[8]  R. R. Robinson,et al.  Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. , 1987, Journal of immunology.

[9]  M. Schiffer,et al.  Reengineering immunoglobulin domain interactions by introduction of charged residues. , 1998, Protein engineering.

[10]  T. Dull,et al.  Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors , 1994 .

[11]  A. Murzin,et al.  The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Vose,et al.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[14]  B. Sandmaier,et al.  Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. , 1998, Biophysical journal.

[15]  P. Iliades,et al.  Triabodies: single chain Fv fragments without a linker form trivalent trimers , 1997, FEBS letters.

[16]  R. Brakenhoff,et al.  Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. , 1998, Blood.

[17]  K. D. Hardman,et al.  An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. , 1993, Protein engineering.

[18]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[19]  A. Wu,et al.  CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  A. Riggs,et al.  Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. , 1990, Cancer research.

[21]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.

[22]  L. Nadler,et al.  Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.

[23]  T. Tedder,et al.  CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.

[24]  L E Williams,et al.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.

[25]  C. Bebbington,et al.  Expression of antibody genes in nonlymphoid mammalian cells , 1991 .

[26]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.

[27]  Terry D. Lee,et al.  Variable flow liquid chromatography-tandem mass spectrometry and the comprehensive analysis of complex protein digest mixtures , 1997 .

[28]  M. Little,et al.  Di‐, tri‐ and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding , 1999, FEBS letters.

[29]  A. Kortt,et al.  ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. , 2000, Protein engineering.

[30]  Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma , 2022 .

[31]  C. Chothia,et al.  Domain association in immunoglobulin molecules. The packing of variable domains. , 1985, Journal of molecular biology.

[32]  M. Little,et al.  Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. , 1994, Journal of immunological methods.

[33]  F. Appelbaum,et al.  Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.

[34]  T. Teeri,et al.  Properties of a single-chain antibody containing different linker peptides. , 1995, Protein engineering.

[35]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. A. Bush,et al.  Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Schlom,et al.  Secretion of a single-gene-encoded immunoglobulin from myeloma cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Change in dimerization mode by removal of a single unsatisfied polar residue located at the interface , 2000, Protein science : a publication of the Protein Society.